DailyMed lists Structured Product Labeling version 7 for the reviewed Leuprolide label family with a published date of 2023-12-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 3 for the reviewed Teriparatide label family with a published date of 2023-12-13. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 217987 with status AP dated 2023-12-06, and names vasopressin among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 210317 with status AP dated 2023-12-05, and names octreotide acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 1 for the reviewed Octreotide label family with a published date of 2023-12-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 5 for the reviewed Ziconotide label family with a published date of 2023-12-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2023-26260, attributed to FDA and its parent HHS department, on 2023-11-30. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ZEGALOGUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dasiglucagon.
DailyMed lists Structured Product Labeling version 15 for the reviewed Abaloparatide label family with a published date of 2023-11-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2023-26255, attributed to FDA and its parent HHS department, on 2023-11-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Empaveli,” and PeptideScanner's exact reviewed identity mapping connects the document to Pegcetacoplan.
DailyMed lists Structured Product Labeling version 6 for the reviewed Setmelanotide label family with a published date of 2023-11-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2023-26106, attributed to FDA and its parent HHS department, on 2023-11-28. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Korsuva,” and PeptideScanner's exact reviewed identity mapping connects the document to Difelikefalin.
DailyMed lists Structured Product Labeling version 2 for the reviewed Teriparatide label family with a published date of 2023-11-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2023-25485, attributed to FDA and its parent HHS department, on 2023-11-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 216075 with status AP dated 2023-11-16, and names ganirelix acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 3 for the reviewed Tirzepatide label family with a published date of 2023-11-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 208569 with status AP dated 2023-11-16, and names teriparatide among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 211097 with status AP dated 2023-11-16, and names teriparatide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 10 for the reviewed Vosoritide label family with a published date of 2023-11-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 2 for the reviewed Tirzepatide label family with a published date of 2023-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 217806 with status AP dated 2023-11-08, and names tirzepatide among the application record's active ingredients.
The Federal Register published notice 2023-24120, attributed to FDA and its parent HHS department, on 2023-11-01. Its official title is “Determination That CALCIUM DISODIUM VERSENATE (Edetate Calcium Disodium) Injection, 200 Milligrams per Milliliter, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.
DailyMed lists Structured Product Labeling version 49 for the reviewed Dulaglutide label family with a published date of 2023-10-18. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 216834 with status AP dated 2023-10-17, and names zilucoplan sodium among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 7 for the reviewed Afamelanotide label family with a published date of 2023-10-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 18 for the reviewed Lixisenatide label family with a published date of 2023-10-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 217569 with status AP dated 2023-09-29, and names vasopressin among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 33 for the reviewed Linaclotide label family with a published date of 2023-09-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 4 for the reviewed Leuprolide label family with a published date of 2023-09-15. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 217159 with status AP dated 2023-09-08, and names motixafortide acetate among the application record's active ingredients.
The Federal Register published notice 2023-19013, attributed to FDA and its parent HHS department, on 2023-09-05. Its official title is “Merck Sharp & Dohme LLC, et al.; Withdrawal of Approval of 35 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin.
DailyMed lists Structured Product Labeling version 1 for the reviewed Leuprolide label family with a published date of 2023-09-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2023-18241, attributed to FDA and its parent HHS department, on 2023-08-24. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Alternative Form of Hearing,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.
The Federal Register published notice 2023-18250, attributed to FDA and its parent HHS department, on 2023-08-24. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.
The Federal Register published notice 2023-18026, attributed to FDA and its parent HHS department, on 2023-08-22. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Tirzepatide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213521 with status AP dated 2023-08-14, and names icatibant acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213966 with status AP dated 2023-08-07, and names daptomycin among the application record's active ingredients.
The Federal Register published notice 2023-16775, attributed to FDA and its parent HHS department, on 2023-08-07. Its official title is “Determination That CUBICIN (Daptomycin) Powder for Injection, 250 Milligrams/Vial and 500 Milligrams/Vial, and CUBICIN RF (Daptomycin) Powder for Injection, 500 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.
DailyMed lists Structured Product Labeling version 6 for the reviewed Semaglutide label family with a published date of 2023-08-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 13 for the reviewed Abaloparatide label family with a published date of 2023-06-28. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 216839 with status AP dated 2023-06-22, and names octreotide acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 32 for the reviewed Linaclotide label family with a published date of 2023-06-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 216807 with status AP dated 2023-06-13, and names octreotide acetate among the application record's active ingredients.
The official Drugs@FDA dataset lists original submission 1 for ANDA 213206 with status AP dated 2023-05-26, and names vasopressin among the application record's active ingredients.
The Federal Register published notice 2023-10710, attributed to FDA and its parent HHS department, on 2023-05-19. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Difelikefalin.
DailyMed lists Structured Product Labeling version 6 for the reviewed Afamelanotide label family with a published date of 2023-05-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 31 for the reviewed Linaclotide label family with a published date of 2023-05-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 48 for the reviewed Dulaglutide label family with a published date of 2023-05-01. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 14 for the reviewed Plecanatide label family with a published date of 2023-04-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2023-06593, attributed to FDA and its parent HHS department, on 2023-03-30. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide.
DailyMed lists Structured Product Labeling version 4 for the reviewed Ziconotide label family with a published date of 2023-03-24. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for ANDA 216904 with status AP dated 2023-03-20, and names desmopressin acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 13 for the reviewed Plecanatide label family with a published date of 2023-03-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 217026 with status AP dated 2023-03-10, and names trofinetide among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 12 for the reviewed Plecanatide label family with a published date of 2023-03-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 5 for the reviewed Semaglutide label family with a published date of 2023-03-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 5 for the reviewed Leuprolide label family with a published date of 2023-03-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The Federal Register published notice 2023-04175, attributed to FDA and its parent HHS department, on 2023-03-01. Its official title is “Mylan Pharmaceuticals Inc., et.al.; Withdrawal of Approval of 11 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant.
The official Drugs@FDA dataset lists original submission 1 for ANDA 215658 with status AP dated 2023-02-28, and names ganirelix acetate among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 4 for the reviewed Semaglutide label family with a published date of 2023-02-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 14 for the reviewed Pramlintide label family with a published date of 2023-02-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
The official Drugs@FDA dataset lists original submission 1 for NDA 217171 with status AP dated 2023-02-17, and names pegcetacoplan among the application record's active ingredients.
The Federal Register published notice 2023-03389, attributed to FDA and its parent HHS department, on 2023-02-17. Its official title is “Determination That MIACALCIN (Calcitonin Salmon) Injection, 100 USP Units/Milliliter (mL), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.
The Federal Register published notice 2023-03364, attributed to FDA and its parent HHS department, on 2023-02-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Afamelanotide, Glucagon, Leuprolide and Vosoritide.
The official Drugs@FDA dataset lists original submission 1 for ANDA 209611 with status AP dated 2023-02-07, and names linaclotide among the application record's active ingredients.
The Federal Register published notice 2023-02442, attributed to FDA and its parent HHS department, on 2023-02-06. Its official title is “Determination That TRIAMCINOLONE ACETONIDE (Triamcinolone Acetonide) Topical Cream, 0.025% and 0.1%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.
The official Drugs@FDA dataset lists original submission 1 for NDA 217415 with status AP dated 2023-01-30, and names daptomycin among the application record's active ingredients.
DailyMed lists Structured Product Labeling version 5 for the reviewed Afamelanotide label family with a published date of 2023-01-24. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
DailyMed lists Structured Product Labeling version 3 for the reviewed Semaglutide label family with a published date of 2023-01-09. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.